Roche’s gantenerumab fails to meet primary endpoint in AD trial

This article was originally published here

The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known

The post Roche’s gantenerumab fails to meet primary endpoint in AD trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply